Crinetics Pharmaceuticals, Inc.
CRNX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$298,408 | -$214,529 | -$163,918 | -$107,641 |
| Dep. & Amort. | $2,785 | $1,098 | $983 | $922 |
| Deferred Tax | $0 | $0 | $0 | $422 |
| Stock-Based Comp. | $69,386 | $40,937 | $28,268 | $17,352 |
| Change in WC | $11,635 | $8,044 | $18,612 | $1,096 |
| Other Non-Cash | -$11,368 | -$1,857 | $850 | -$739 |
| Operating Cash Flow | -$225,970 | -$166,307 | -$115,205 | -$88,588 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$3,844 | -$4,688 | -$1,656 | -$436 |
| Net Acquisitions | $0 | $0 | $0 | $422 |
| Inv. Purchases | -$1,146,772 | -$532,857 | -$329,817 | -$125,404 |
| Inv. Sales/Matur. | $575,799 | $337,132 | $157,493 | $69,357 |
| Other Inv. Act. | $0 | $0 | $0 | -$422 |
| Investing Cash Flow | -$574,817 | -$200,413 | -$173,980 | -$56,483 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $970,048 | $369,019 | $117,242 | $249,542 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $40,387 | $19,925 | $4,721 | $3,137 |
| Financing Cash Flow | $1,010,435 | $388,944 | $121,963 | $252,679 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $209,648 | $22,224 | -$167,222 | $107,608 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $56,197 | $33,973 | $201,195 | $93,587 |
| End Cash | $265,845 | $56,197 | $33,973 | $201,195 |
| Free Cash Flow | -$229,814 | -$170,995 | -$116,861 | -$89,024 |